Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy

Dick De Zeeuw, Giuseppe Remuzzi, Hans Henrik Parving, William F. Keane, Zhongxin Zhang, Shahnaz Shahinfar, Steve Snapinn, Mark E. Cooper, William E. Mitch, Barry M. Brenner

Research output: Contribution to journalArticlepeer-review


Background-Albuminuria is an established risk marker for both cardiovascular and renal outcomes. Albuminuria can be reduced with drugs that block the renin-angiotensin system (RAS). We questioned whether the short-term drug-induced change in albuminuria would predict the long-term cardioprotective efficacy of RAS intervention. Methods and Results-We analyzed data from Reduction in Endpoints in Non-insulin dependent diabetes mellitus with the Angiotensin II Antagonist Losartan (RENAAL), a double-blind, randomized trial in 1513 type 2 diabetic patients with nephropathy, focusing on the relationship between the prespecified cardiovascular end point (composite) or hospitalization for heart failure and baseline or reduction in albuminuria. Patients with high baseline albuminuria (≥3 g/g creatinine) had a 1.92-fold (95% CI, 1.54 to 2.38) higher risk for the cardiovascular end point and a 2.70-fold (95% CI, 1.94 to 3.75) higher risk for heart failure compared with patients with low albuminuria (

Original languageEnglish
Pages (from-to)921-927
Number of pages7
Issue number8
Publication statusPublished - Aug 24 2004


  • Albuminuria
  • Angiotensin
  • Cardiovascular disease
  • Diabetes
  • Proteinuria

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy'. Together they form a unique fingerprint.

Cite this